UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Super Group (SGHC) Limited
(Name of Subject Company and Filing Person (Issuer))
Warrants to Acquire Ordinary Shares
(Title of Class of Securities)
G8588X111
(CUSIP Number of Class of Securities)
Robert James Dutnall
Super Group (SGHC) Limited
Bordeaux Court, Les Echelons
St. Peter Port, Guernsey, GY1 1AR
Telephone: +44 (0) 1481-822-939
(Name, address and telephone numbers, of person authorized to receive notices and communications on behalf of filing persons)
Copies of communications to:
Justin Stock
David Boles
Brian Leaf
Cooley LLP
55 Hudson Yards
10001 New York, NY
Tel: +1 212-479-6000
| ☐ | Check the box if the filing relates solely to preliminary communications before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates: |
| ☐ | third-party tender offer subject to Rule 14d-1. |
| ☒ | issuer tender offer subject to Rule 13e-4. |
| ☐ | going-private transaction subject to Rule 13e-3. |
| ☐ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
| ☐ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |
| ☐ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) |
EXPLANATORY NOTE
This Amendment No. 1 (“Amendment No. 1”) amends the prospectus/offer to exchange, dated November 10, 2022 (as it may be amended and supplemented from time to time, the “Prospectus/Offer to Exchange”), a copy of which was filed as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO originally filed by Super Group (SGHC) Limited, a non-cellular company limited by shares incorporated under the laws of the Island of Guernsey (the “Company”), on November 10, 2022 (as it may be amended and supplemented from time to time, the “Schedule TO”), relating to an offer by the Company to each holder of the Company’s outstanding public warrants (as defined below) to receive 0.25 ordinary shares of the Company, no par value per share (“Ordinary Shares”) in exchange for every outstanding public warrant tendered by the holder and exchanged pursuant to the offer (the “Offer”).
The 22,499,986 redeemable warrants sold as part of the units in Sports Entertainment Acquisition Corp.’s (“SEAC”) initial public offering of SEAC’s securities on October 6, 2020 (the “IPO”) (whether they were purchased in the IPO or thereafter in the open market) are referred to herein as the “public warrants”. The warrants originally issued to certain investors in a private placement simultaneously with the closing of the IPO, as well as in connection with the closing of the partial exercise by the underwriters of their over-allotment option, that have not become public warrants under the Warrant Agreement (as defined below) as a result of being transferred to any person other than permitted transferees are referred to herein as the “private placement warrants”, and were issued pursuant to certain subscription agreements, each in connection with the closing of the transactions contemplated by the business combination agreement, dated as of April 23, 2021, by and among SEAC and the Company, et al.
The public warrants and the private placement warrants are referred to herein collectively as the “warrants”, and each a “warrant”.
Concurrently with the Offer, the Company is also soliciting consents (the “Consent Solicitation”) from holders of the outstanding warrants to amend that certain Warrant Agreement, dated as of October 6, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agreement”), to permit the Company to (i) require that all outstanding public warrants following this Offer be converted into 0.225 Ordinary Shares (a ratio 10% less than the exchange ratio applicable to the Offer) and (ii) instruct the warrant agent to cancel each outstanding private placement warrant for no consideration (the “Warrant Amendment”).
The Prospectus/Offer to Exchange, a copy of which is filed herewith as Exhibit (a)(1)(A), is amended to, among other things, (i) clarify that all offer conditions must be satisfied or waived as of the expiration of the offer, (ii) remove the limitation on prices for securities in U.S. securities or financial markets as a condition to the Offer, (iii) clarify that the Company’s action or inaction may not cause a failure of a condition to the Offer, (iv) clarify that upon occurrence of an event that implicates a condition to the Offer, the Company will promptly notify warrant holders of whether it intends to waive the condition, (v) remove language related to the Company’s reservation of the right to redeem the warrants, (vi) include as an exhibit the press release issued by the Company on November 22, 2022 with the Company’s third quarter 2022 financial results, and (vii) furnish updated Interactive Data (XBRL) files as Exhibit 101, in accordance with Rule 405 of Regulation S-T. In accordance with (v) above, corresponding edits have been made to other exhibits to this Schedule TO and to the Prospectus/Offer to Exchange to remove language related to the Company’s reservation of rights to redeem the warrants. No other changes have been made to the Prospectus/Offer to Exchange or the financial statements contained therein as originally filed on November 10, 2022.
Except as amended hereby to the extent discussed above, the information contained in the Schedule TO, the Prospectus/Offer to Exchange, and the other exhibits to the Schedule TO remains unchanged and is hereby expressly incorporated into this Amendment No. 1 by reference. This Amendment No. 1 should be read with the Schedule TO and the Prospectus/Offer to Exchange.
1
Item 1. Summary Term Sheet.
The information set forth in the section of the Prospectus/Offer to Exchange entitled “Summary” is incorporated herein by reference.
Item 2. Subject Company Information.
| (a) | Name and Address. The name of the issuer is Super Group (SGHC) Limited. The Company’s principal executive offices are located at Bordeaux Court, Les Echelons, St. Peter Port, Guernsey, GY1 1AR, and its telephone number at such offices is +44 (0) 14 8182-2939. |
| (b) | Securities. The subject securities are: |
| • | the 22,499,986 redeemable public warrants sold as part of the units in SEAC’s IPO (whether they were purchased in the IPO or thereafter in the open market). |
Each warrant entitles the holder to purchase one of our Ordinary Shares at an exercise price of $11.50 per share, subject to adjustment pursuant to the Warrant Agreement. The public warrants are listed on the New York Stock Exchange under the symbol “SGHC WS.” As of November 9, 2022, 33,499,986 warrants were outstanding, consisting of 22,499,986 public warrants and 11,000,000 private placement warrants.
| (c) | Trading Market and Price. The information set forth in the section of the Prospectus/Offer to Exchange entitled “Market Information, Dividends and Related Shareholder Matters” is incorporated herein by reference. |
Item 3. Identity and Background of Filing Person.
| (a) | Name and Address. The Company is the filing person and the issuer. The information set forth above under Item 2(a) is incorporated herein by reference. The Company’s directors and executive officers as of November 10, 2022 are listed in the table below. |
| Name |
Position | |
| Neal Menashe |
Chief Executive Officer and Director | |
| Alinda Van Wyk |
Chief Financial Officer and Director | |
| Richard Hasson |
President, Chief Operating Officer and Director | |
| Eric Grubman |
Director, Chairman | |
| John Collins |
Director | |
| Robert James Dutnall |
Director | |
| John Le Poidevin |
Director | |
| Natara Holloway Branch |
Director | |
| Jonathan Jossel |
Director |
The information set forth in the section of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation-Interests of Directors, Executive Officers, and Others” is incorporated herein by reference.
Item 4. Terms of the Transaction.
| (a) | Material Terms. The information set forth in the sections of the Prospectus/Offer to Exchange entitled “Summary” and “The Offer and Consent Solicitation” is incorporated herein by reference. |
| (b) | Purchases. The information set forth in the section of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation—Interests of Directors, Executive Officers, and Others” is incorporated herein by reference. |
2
Item 5. Past Contracts, Transactions, Negotiations and Agreements.
| (a) | Agreements Involving the Subject Company’s Securities. The information set forth in the sections of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation,” “Market Information, Dividends and Related Shareholder Matters—Transactions and Agreements Concerning Our Securities,” “Description of Securities,” and “Certain Relationships and Related Person Transactions” is incorporated herein by reference. |
Item 6. Purposes of the Transaction and Plans or Proposals.
| (a) | Purposes. The information set forth in the section of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation—Background and Purpose of the Offer and Consent Solicitation” is incorporated herein by reference. |
| (b) | Use of Securities Acquired. The information set forth in the section of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation—Background and Purpose of the Offer and Consent Solicitation” is incorporated herein by reference. |
| (c) | Plans. From time to time, as part of the Company’s long-term corporate goal of enhancing shareholder value, it may explore potential strategic transactions. The Company currently has no definitive plan or proposal to conduct any strategic transaction. The Company may decide to engage in one or more such transactions in the future, if, among other things, its Board of Directors determines that any such transactions are in the best interest of the Company. There is no assurance that a strategic transaction or transactions will occur or that liquidity or enhanced value will be realized by the Company or its shareholders from any such transaction. |
Except as described above and in the sections of the Prospectus/Offer to Exchange entitled “Risk Factors” and “The Offer and Consent Solicitation,” which are incorporated by reference herein, neither the Company, nor any of its directors, executive officers, or controlling persons, or any executive officers, directors, managers or partners of its controlling persons, has any plans, proposals or negotiations that relate to or would result in: (1) any extraordinary transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; (2) any purchase, sale or transfer of a material amount of assets of the Company or any of its subsidiaries; (3) any material change in the present dividend rate or policy, indebtedness or capitalization of the Company; (4) any change in the present board of directors or management of the Company, including, but not limited to, any plans or proposals to change the number or the term of directors or to fill any existing vacancies on the board or to change any material term of the employment contract of any executive officer; (5) any other material change in the Company’s corporate structure or business; (6) any class of equity securities of the Company to be delisted from the New York Stock Exchange; (7) any class of equity securities of the Company becoming eligible for termination of registration under section 12(g)(4) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); (8) the suspension of the Company’s obligation to file reports under Section 15(d) of the Exchange Act; (9) the acquisition by any person of additional securities of the Company, or the disposition of securities of the Company; or (10) any changes in the Company’s charter, bylaws or other governing instruments or other actions that could impede the acquisition of control of the Company.
Item 7. Source and Amount of Funds or Other Consideration.
| (a) | Source of Funds. The information set forth in the section of the Prospectus/Offer to Exchange entitled “Market Information, Dividends and Related Shareholder Matters—Source and Amount of Funds” is incorporated herein by reference. |
| (b) | Conditions. Not applicable. |
| (c) | Borrowed Funds. Not applicable. |
3
Item 8. Interest in Securities of the Subject Company.
| (a) | Securities Ownership. The information set forth in the section of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation—Interests of Directors, Executive Officers, and Others” is incorporated herein by reference. |
| (b) | Securities Transactions. Except as set forth in the section of the Prospectus/Offer to Exchange entitled “Market Information, Dividends and Related Shareholder Matters—Transactions and Agreements Concerning Our Securities,” which is incorporated by reference herein, neither the Company, nor any of its directors, executive officers or controlling persons, or any executive officers, directors, managers or partners of any of its controlling persons, has engaged in any transactions in the public warrants in the last 60 days. |
Item 9. Persons/Assets, Retained, Employed, Compensated or Used.
| (a) | Solicitations or Recommendations. The information set forth in the section of the Prospectus/Offer to Exchange entitled “Market Information, Dividends and Related Shareholder Matters—Fees and Expenses” is incorporated herein by reference. None of the Company, its management, its board of directors, the information agent or the exchange agent for the Offer is making any recommendation as to whether holders of public warrants should tender public warrants for exchange in the Offer. |
Item 10. Financial Statements.
| (a) | Financial Information. The financial statements and other financial information of the Company included in the Prospectus/Offer to Exchange are incorporated by reference herein. The full text of such financial statements and other financial information, as well as the other documents the Company has filed with the SEC prior to, or will file with the SEC subsequent to, the filing of this Schedule TO relating to the Offer are available for inspection and copying from the SEC’s website at www.sec.gov. |
| (b) | Pro Forma Information. The pro forma financial information set forth in the sections of the Prospectus/Offer to Exchange entitled “Summary Unaudited Pro Forma Condensed Financial Information” and “Pro Forma Condensed Combined Financial Information” is incorporated herein by reference. |
Item 11. Additional Information.
| (a) | Agreements, Regulatory Requirements and Legal Proceedings. |
| (1) | The information set forth in the sections of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation—Agreements, Regulatory Requirements and Legal Proceedings” and “Certain Relationships and Related Transactions” is incorporated herein by reference. |
| (2) | The information set forth in the section of the Prospectus/Offer to Exchange entitled “The Offer and Consent Solicitation—Agreements, Regulatory Requirements and Legal Proceedings” is incorporated herein by reference. |
| (3) | Not applicable. |
| (4) | Not applicable. |
| (5) | None. |
| (b) | Not applicable. |
4
Item 12. Exhibits.
| (a) | Exhibits |
5
Filing Fee Exhibit. Item 13. Information Required By Schedule 13E-3. Not applicable. 6
SIGNATURES After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and
correct. /s/ Robert James Dutnall Dated: November 22, 2022 7
(b)
SUPER GROUP (SGHC) LIMITED
By:
Robert James Dutnall
Authorized Signatory
Exhibit 107
Calculation of Filing Fee Tables
Schedule TO
(Form Type)
Super Group (SGHC)
(Exact Name of Registrant as Specified in its Charter)
Table 1—Transaction Valuation
| Transaction Valuation(1) |
Fee Rate |
Amount of Filing Fee(2) | ||||
| Fees to Be Paid |
$13,274,991.74 | $110.20 per $1,000,000 | $1,462.91 | |||
| Fees Previously Paid |
||||||
| Total Transaction Valuation |
$1,462.91 | |||||
| Total Fees Due for Filing |
$1,462.91 | |||||
| Total Fee Offsets |
— | |||||
|
Net Fee Due |
$1,462.91 | |||||
| (1) | The transaction valuation is estimated solely for purposes of calculating the amount of the filing fee. Super Group (SGHC) Limited (the “Company”) is offering holders of a total of 22,499,986 public warrants to purchase ordinary shares of the Company, no par value per share (“Ordinary Shares”) the opportunity to exchange such warrants and receive 0.25 Ordinary Shares in exchange for each warrant. The transaction value was determined by using the average of the high and low prices of the public warrants as reported on the New York Stock Exchange on November 3, 2022, which was $0.59 per public warrant. |
| (2) | The amount of the filing fee assumes that all outstanding public warrants of the Company will be exchanged. |